HIV感染男男性行为者急性丙型肝炎早期治疗的成本效果分析数据集
该数据集包含荷兰HIV感染MSM人群中急性丙型肝炎早期DAA治疗成本效果分析的数学模型参数和结果。

基本信息
资源简介
HIV感染男男性行为者急性丙型肝炎早期治疗的成本效果分析数据集
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集,收录 9 个文件、合计 1.91 MB,主题涵盖 hepatitis C infection、hepatitis C virus infections、HIV-infected MSM、F 2 treatment、QALY,可用于统计建模、特征工程与队列分析,CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men》。配套论文《Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men》发表于 PLOS ONE(2019),DOI:10.1371/journal.pone.0210179。源站首次发布:2019-01-10。
【数据内容】
源站原始描述:Background Treatment of hepatitis C virus infections (HCV) with direct acting antivirals (DAA) can prevent new infections since cured individuals cannot transmit HCV. However, as DAAs are expensive, many countries defer treatment to advances stages of fibrosis, which results in ongoing transmission. We assessed the epidemiological impact and cost-effectiveness of treatment initiation in different stages of infection in the Netherlands where the epidemic is mainly concentrated among HIV-infected…
【数据结构与技术规格】
文件数 9 个,合计 1.91 MB。pone.0210179.s001.pdf:application/pdf,329.82 KB。pone.0210179.s002.pdf:application/pdf,350.55 KB。pone.0210179.s003.pdf:application/pdf,350.26 KB。数据集 DOI:10.1371/journal.pone.0210179。
【主题与分类】
源站学科分类:Medicine、Microbiology、Pharmacology、Biotechnology、Evolutionary Biology、Cancer。主题标签:hepatitis C infection、hepatitis C virus infections、HIV-infected MSM、F 2 treatment、QALY、Dutch HCV epidemic、F 2、ICER、Results Immediate DAA treatment、DAA treatment scenarios。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面:https://plos.figshare.com/articles/dataset/Early_treatment_of_acute_hepatitis_C_infection_is_cost-effective_in_HIV-infected_men-who-have-sex-with-men/7573574
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:Popping, Stephanie; Hullegie, Sebastiaan J.; Boerekamps, Anne; J. A. Rijnders, Bart; J. de Knegt, Robert; K. Rockstroh, Jürgen; et al. (2019). Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLOS ONE. Dataset
【使用注意】
· 源站最后修改于 2023-06-06,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务(收技术服务费,非数据销售)
暂未开放当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men
- DOI:10.1371/journal.pone.0210179
- 发布日期:2019-01-10
- 文件数:9 个
- 文件总体积:1.91 MB
- 源站页面:https://plos.figshare.com/articles/dataset/Early_treatment_of_acute_hepatitis_C_infection_is_cost-effective_in_HIV-infected_men-who-have-sex-with-men/7573574
命令行下载
curl -L -o "pone.0210179.s001.pdf" "https://ndownloader.figshare.com/files/14069237"
curl -L -o "pone.0210179.s002.pdf" "https://ndownloader.figshare.com/files/14069240"
curl -L -o "pone.0210179.s003.pdf" "https://ndownloader.figshare.com/files/14069243"
curl -L -o "pone.0210179.s004.pdf" "https://ndownloader.figshare.com/files/14069246"
curl -L -o "pone.0210179.s005.pdf" "https://ndownloader.figshare.com/files/14069249"
curl -L -o "pone.0210179.s006.pdf" "https://ndownloader.figshare.com/files/14069252"
curl -L -o "pone.0210179.s007.pdf" "https://ndownloader.figshare.com/files/14069255"
curl -L -o "pone.0210179.s008.pdf" "https://ndownloader.figshare.com/files/14069258"
文件清单
pone.0210179.s001.pdf(329.82 KB)pone.0210179.s002.pdf(350.55 KB)pone.0210179.s003.pdf(350.26 KB)pone.0210179.s004.pdf(102.11 KB)pone.0210179.s005.pdf(127.52 KB)pone.0210179.s006.pdf(102.50 KB)pone.0210179.s007.pdf(81.97 KB)pone.0210179.s008.pdf(86.99 KB)pone.0210179.s009.pdf(374.04 KB)
文件总体积 1.91 MB(源站 API 实测)。
数据加载示例(图像类)
from PIL import Image
import glob, os
files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
+ glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)
# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path) # 要求 子目录=类别
目录组织与标注格式以源站说明和下载后实际文件为准。
数据说明
Background
Treatment of hepatitis C virus infections (HCV) with direct acting antivirals (DAA) can prevent new infections since cured individuals cannot transmit HCV. However, as DAAs are expensive, many countries defer treatment to advances stages of fibrosis, which results in ongoing transmission. We assessed the epidemiological impact and cost-effectiveness of treatment initiation in different stages of infection in the Netherlands where the epidemic is mainly concentrated among HIV-infected MSMs.
Methods
We calibrated a deterministic mathematical model to the Dutch HCV epidemic among HIV-infected MSM to compare three different DAA treatment scenarios: 1) immediate treatment, 2) treatment delayed to chronic infection allowing spontaneous clearance to occur, 3) treatment delayed until F2 fibrosis stage. All scenarios are simulated from 2015 onwards. Total costs, quality adjusted life years (QALY), incremental cost-effectiveness ratios (ICERs), and epidemiological impact were calculated from a providers perspective over a lifetime horizon. We used a DAA price of €35,000 and 3% discounting rates for cost and QALYs.
Results
Immediate DAA treatment lowers the incidence from 1.2/100 person-years to 0.2/100 person-years (interquartile range 0.1–0.2) and the prevalence from 5.0/100 person-years to 0.5/100 person-years (0.4–0.6) after 20 years. Delayed treatment awaiting spontaneous clearance will result in a similar reduction. However, further delayed treatment to F2 will increases the incidence and prevalence. Earlier treatment will cost society €68.3 and €75.1 million over a lifetime for immediate and awaiting until the chronic stage, respectively. The cost will increase if treatment is further delayed until F2 to €98.4 million. Immediate treatment will prevent 7070 new infections and gains 3419 (3019–3854) QALYs compared to F2 treatment resulting in a cost saving ICER. Treatment in the chronic stage is however dominated.
Conclusions
Early DAA treatment for HIV-infected MSM is an excellent and sustainable tool to meet the WHO goal of eliminating HCV in 2030.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.1371/journal.pone.0210179(source: https://plos.figshare.com/articles/dataset/Early_treatment_of_acute_hepatitis_C_infection_is_cost-effective_in_HIV-infected_men-who-have-sex-with-men/7573574)。
数据缺失?
依托陕西、四川两大基地,我们与超过十家三甲医院建立直接合作关系,覆盖合规授权、采集治理、专业标注、数据交付的全流程,为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务?立即联系我们获取专业方案。




